HIV vaccine development.

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Updates on the Thai clinical vaccine trial, the discovery of additional neutralizing antibodies, and several new, nonhuman primate vaccine studies were presented at the 17th Conference on Retroviruses and Opportunistic Infections this year. Interestingly, the vaccine effect observed in the Thai trial diminished with time and was most effective in individuals who reported low-risk behavior. Two new neutralizing monoclonal antibodies were reported that were more potent and broadly reactive than the previously described monoclonal antibodies, giving the neutralization field an important boost. New studies were presented in macaques showing that a DNA prime modified vaccinia virus Ankara boost regimen can reduce acquisition of infection after a low-dose mucosal challenge with a heterologous pathogenic simian immunodeficiency virus (SIV) strain. Data suggesting that attenuated SIV vaccines can induce cellular immune responses that control viral replication were also discussed. Finally, and perhaps most encouragingly, vaccination with cytomegalovirus-expressing SIV antigens provided robust levels of protection against the highly pathogenic SIVmac239 viral isolate. All of these promising results should serve to energize the HIV vaccine field.

Original languageEnglish
Pages (from-to)35-36
Number of pages2
JournalTopics in HIV medicine : a publication of the International AIDS Society, USA
Volume18
Issue number2
StatePublished - Apr 1 2010
Externally publishedYes

Fingerprint

AIDS Vaccines
Simian Immunodeficiency Virus
Vaccines
Neutralizing Antibodies
Monoclonal Antibodies
Vaccinia virus
Macaca
Risk-Taking
Cytomegalovirus
Cellular Immunity
Primates
Vaccination
Clinical Trials
Antigens
DNA
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

HIV vaccine development. / Watkins, David.

In: Topics in HIV medicine : a publication of the International AIDS Society, USA, Vol. 18, No. 2, 01.04.2010, p. 35-36.

Research output: Contribution to journalArticle

@article{6e8a8e73411048d794c9b708d50c9b70,
title = "HIV vaccine development.",
abstract = "Updates on the Thai clinical vaccine trial, the discovery of additional neutralizing antibodies, and several new, nonhuman primate vaccine studies were presented at the 17th Conference on Retroviruses and Opportunistic Infections this year. Interestingly, the vaccine effect observed in the Thai trial diminished with time and was most effective in individuals who reported low-risk behavior. Two new neutralizing monoclonal antibodies were reported that were more potent and broadly reactive than the previously described monoclonal antibodies, giving the neutralization field an important boost. New studies were presented in macaques showing that a DNA prime modified vaccinia virus Ankara boost regimen can reduce acquisition of infection after a low-dose mucosal challenge with a heterologous pathogenic simian immunodeficiency virus (SIV) strain. Data suggesting that attenuated SIV vaccines can induce cellular immune responses that control viral replication were also discussed. Finally, and perhaps most encouragingly, vaccination with cytomegalovirus-expressing SIV antigens provided robust levels of protection against the highly pathogenic SIVmac239 viral isolate. All of these promising results should serve to energize the HIV vaccine field.",
author = "David Watkins",
year = "2010",
month = "4",
day = "1",
language = "English",
volume = "18",
pages = "35--36",
journal = "Topics in antiviral medicine",
issn = "2161-5853",
publisher = "International Antiviral Society",
number = "2",

}

TY - JOUR

T1 - HIV vaccine development.

AU - Watkins, David

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Updates on the Thai clinical vaccine trial, the discovery of additional neutralizing antibodies, and several new, nonhuman primate vaccine studies were presented at the 17th Conference on Retroviruses and Opportunistic Infections this year. Interestingly, the vaccine effect observed in the Thai trial diminished with time and was most effective in individuals who reported low-risk behavior. Two new neutralizing monoclonal antibodies were reported that were more potent and broadly reactive than the previously described monoclonal antibodies, giving the neutralization field an important boost. New studies were presented in macaques showing that a DNA prime modified vaccinia virus Ankara boost regimen can reduce acquisition of infection after a low-dose mucosal challenge with a heterologous pathogenic simian immunodeficiency virus (SIV) strain. Data suggesting that attenuated SIV vaccines can induce cellular immune responses that control viral replication were also discussed. Finally, and perhaps most encouragingly, vaccination with cytomegalovirus-expressing SIV antigens provided robust levels of protection against the highly pathogenic SIVmac239 viral isolate. All of these promising results should serve to energize the HIV vaccine field.

AB - Updates on the Thai clinical vaccine trial, the discovery of additional neutralizing antibodies, and several new, nonhuman primate vaccine studies were presented at the 17th Conference on Retroviruses and Opportunistic Infections this year. Interestingly, the vaccine effect observed in the Thai trial diminished with time and was most effective in individuals who reported low-risk behavior. Two new neutralizing monoclonal antibodies were reported that were more potent and broadly reactive than the previously described monoclonal antibodies, giving the neutralization field an important boost. New studies were presented in macaques showing that a DNA prime modified vaccinia virus Ankara boost regimen can reduce acquisition of infection after a low-dose mucosal challenge with a heterologous pathogenic simian immunodeficiency virus (SIV) strain. Data suggesting that attenuated SIV vaccines can induce cellular immune responses that control viral replication were also discussed. Finally, and perhaps most encouragingly, vaccination with cytomegalovirus-expressing SIV antigens provided robust levels of protection against the highly pathogenic SIVmac239 viral isolate. All of these promising results should serve to energize the HIV vaccine field.

UR - http://www.scopus.com/inward/record.url?scp=77955974521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955974521&partnerID=8YFLogxK

M3 - Article

C2 - 20516522

AN - SCOPUS:77955974521

VL - 18

SP - 35

EP - 36

JO - Topics in antiviral medicine

JF - Topics in antiviral medicine

SN - 2161-5853

IS - 2

ER -